Mining featured micro ribonucleic acids associated with lung cancer based on bioinformatics

Lin Su1, Na Li2 & Xueyun Huo1

1 Department of Respiratory, The Fourth People’s Hospital of Jinan, Jinan Clinical School of Taishan Medical College, Jinan, China
2 Department of Clinical Pharmacy, The Fourth People’s Hospital of Jinan, Jinan Clinical School of Taishan Medical College, Jinan, China

Keywords
Differentially expressed genes; DNA microarray; lung cancer; miRNA.

Correspondence
Xueyun Huo, No. 50 Shifan Road, Tianqiao district, Jinan 250031, China.
Tel: +86 0531 8131 3114
Fax: +86 0531 8131 2668
Email: firexueyun@163.com

Received: 14 August 2014;
Accepted: 25 September 2014.
doi: 10.1111/1759-7714.12187

Thoracic Cancer 6 (2015) 501–507

Abstract

Background: Few genetic markers useful for the screening of lung cancer risk exist. Although related research has shown that certain expression profiles of micro ribonucleic acids (miRNAs) are different in lung cancer versus the normal lung, such as miR-29a and miR-29s, the precise molecular mechanism of lung cancer remains obscure. In order to get a better understanding of the pathogenetic mechanism of lung cancer, we analyzed the differentially expressed genes (DEGs) and identified featured miRNAs in lung cancer tissues.

Methods: We used the gene expression profile GSE10072, including 49 gene chips of non-tumor tissues and 58 gene chips of lung tumor specimens. The DEGs between these two groups were identified by Limma package in R language. The TarBase database was used to construct the networks of miRNA regulating DEGs related to lung cancer. After ordering miRNAs regulating DEGs, we further screened featured miRNAs combined with the miR2Disease database.

Results: A total of 5572 DEGs were obtained between lung cancer and control specimens. After constructing a miRNA regulatory network, a total of 398 regulations between 57 miRNAs and 321 target genes existed. By intergrating the miR2Disease database and using a sorting algorithm, a total of six featured miRNAs related to lung cancer were identified, including miR-520h, miR-133a, miR-34, miR-103, miR-370, and miR-148. They might be involved in lung cancer progression by regulating ABCG2, PKM2, VAMP2, GPD1, MAP3K8, and DNMT3B, respectively.

Conclusion: The top 10 significant miRNAs, such as miR-520h, miR-133a, miR-34, and miR-103 may be potential therapeutic targets for lung cancer.

Introduction

Lung cancer is one of the leading causes of cancer-related deaths in the world, largely because of the genetic and epigenetic damage caused by tobacco smoke. In general, lung cancer is divided into two categories for the purpose of diagnosis and treatment: small cell lung carcinoma and non-small cell lung carcinomas (NSCLCs). Both classifications are difficult to diagnose at an early stage and are always related to poor survival. To improve the patient survival rate, it is critical to investigate the mechanism of tumorigenesis in lung cancer in order to determine effective therapies.

Recently, molecular investigations have provided evidence that the development of lung cancer is involved with genetic alterations, which has contributed to defining the molecular network of lung carcinogenesis. The expressions of Kirsten rat sarcoma viral oncogene homolog (K-ras), phosphatase and tensin homolog (PTEN), fragile histidine triad gene (FHIT) and myosin XVIIIB (MYO1B) are frequently altered. Studies also show that p53 and RB/p16 pathways are usually deficient. In addition, some unknown markers, such as noncoding RNA gene products, may lend insight into lung cancer. Micro ribonucleic acids (miRNAs) are small noncoding RNA gene products considered to be important regulators of gene expression and play a crucial role in cellular growth, differentiation, and death. Some miRNA expression levels are closely related with human tumorigenesis. It is reported that miR-29 seconds is inversely correlated to DNA (cytosine-5’)-methyltransferase 3 alpha (DNMT3A) and DNA (cytosine-5’)-methyltransferase 3 beta (DNMT3B) in lung cancer tissues and plays a role in the epigenetic normalization of NSCLCs. Let-7 microRNA, as a tumor suppressor
gene, has been demonstrated to directly repress cancer growth in the lung. Although numerous studies have contributed to exploring the mechanisms of lung cancer, the role of miRNAs in lung cancer progression is not yet clarified.

In our study, a set of gene expression profiles of lung cancer and controls were analyzed to identify the differentially expressed genes (DEGs). We then applied bioinformatics tools to identify miRNAs regulating DEGs. Using TarBase and the MiR2Disease database, we further screened featured miRNA involved in the occurrence of lung cancer. Our work may help to seek potential targets for lung cancer therapies.

Methods and data

Affymetrix microarray data

Gene expression profiles under the accession number GSE10072 were downloaded from the Gene Expression Omnibus (GEO). A total of 107 samples were used for the development of a microarray profile, which contained 58 NSCLC tissues, including 16 from never smokers (NS), 18 from former smokers (FS), 24 from current smokers (CS), and 49 normal samples, which included 15 NS, 18 FS, and 16 CS. There was no significant difference in the number of smokers between the two groups. The raw data were obtained based on the GPL96 Platform.

Data preprocessing and screening of lung cancer related genes

The probe-level data in CEL files were converted into expression profiles; MAS 5.0 performed background correction and standard summarization. For genes corresponding to multiple probe sets, which have a plurality of expression values, the gene expression values of those probe sets were averaged. Eventually, a total of 12 752 gene expression profiles were obtained, including 58 lung cancer and 49 control specimens.

CancerResource (http://bioinformatics.charite.de/cancerresource/) is a database integrating cancer-relevant relationships of compounds and targets. A total of 211 lung cancer-related genes were obtained from CancerResource and 209 genes were involved in gene expression profiles.

Differentially expressed gene (DEG) analysis

A Limma package in R language was used to analyze the DEGs between the 58 lung cancer and 49 control specimens. The P-values were adjusted by the Benjamin and Hochberg (BH) method based on the multtest package. A fold discovery rate (FDR) of <0.01 was used as the cut-off criterion for DEGs. To get a better understanding of DEGs, the expression values of the DEGs were collected and hierarchical clustering analysis was performed based on Euclidean distance. An enrichment analysis of DEGs corresponding to lung cancer-related genes was then performed using the Fisher test. To facilitate the analysis, we named the DEGs related to lung cancer (P < 0.01) as annotated differentially expressed genes (ADEGs).

Micro ribonucleic acid (MiRNA) regulating DEG network analysis

TarBase (http://diana.cslab.ece.ntua.gr/DianaToolsNew/index.php?r=tarbase/index) is a database providing a collection of all experimentally tested miRNA targets. A total of 1094 miRNA-target interactions in humans were selected based on TarBase data. miRNA–targeted DEG regulation networks were constructed and the regulated relations, target genes, and miRNAs were calculated.

Screening of featured miRNAs related to lung cancer

After miRNA-targeted DEG regulation networks were obtained, we aimed to further identify featured miRNAs related to lung cancer. In this study, we applied a ranking approach to obtain featured miRNAs. The Rank value of miRNA regulating DEGs were calculated according to:

$$\text{Rank}_{\text{value}}(i) = \frac{\sum_{j=1}^{n} \text{DEG}_{\text{Rank}}(j)}{n}$$

where DEG_{Rank}(j) is the rank of certain DEG in all DEGs. Featured miRNAs were endowed with a smaller rank value. We then tested whether DEGs were related to lung cancer genes by calculating the rank sum of ADEGs and randomly selecting the same amount of DEGs. The procedure was repeated 1000 times. We then calculated the average of the random rank sum, variance, and P-value by Z-score test. We also ranked miRNAs regulating DEGs.

The miR2Disease database (http://www.mir2disease.org) is a manually curated database that aims to provide a comprehensive record of miRNA deregulation involved in various human diseases. A total of 42 lung cancer-related genes were stored in the miR2Disease database. We mapped DEGs in miRNA regulating networks into the miR2Disease database to further screen miRNAs.

Results

Screening of DEGs and annotated DEGs

We obtained the publicly available microarray dataset GSE10072 from the GEO database. A Limma package in R language was used to analyze the DEGs between 58 lung cancer tissues and 49 non-tumor samples. According to threshold criterion (FDR < 0.01) for DEGs, there were 5572
DEGs. The results of hierarchical clustering are shown in a heat map (Fig 1). Genes with similar expression levels were collected together and samples (case and control) were relatively distinguished based on the gene expression profiles. By integrating the CancerResource database, DEGs were significantly enriched in ADEGs ($P$-value = 0.001171), which suggested that the DEGs identified in this work were efficient.

**miRNA regulating DEG network analysis**

We constructed miRNA-targeted DEG networks using the TarBase database and obtained 398 regulations between 57 miRNAs (such as miR-520h, miR-133a, miR-103, miR-34, miR-370, and miR-148) and 321 DEGs (such as SMAD family member 6 [SMAD6], adenosine 5′-triphosphate-binding cassette, sub-family G [WHITE], member 2 [ABCG2], pyruvate...
kinase, muscle [PKM2], mitogen-activated protein kinase 8 [MAP3K8], vesicle-associated membrane protein 2 [VAMP2], glycerol-3-phosphate dehydrogenase 1 [GPD1] and DNA (cytosine-5-)-methyltransferase 3 beta) [DNMT3B]) (Fig 2).

Screening of featured miRNAs related to lung cancer

There were 115 ADEGs among the DEGs identified in our paper. Their rank sum was 300251. We randomly selected 115 DEGs and calculated rank sum, variance, and P-value. Their value was 321423.8, 16512.12, and 0.09 respectively. These data showed that lung cancer-related genes ranked highest among the DEGs. We screened the significant miRNAs associated with lung cancer by ordering 57 miRNAs (Table 1). Using the miR2Disease to search for the 57 miRNAs, we found that there were 11 overlapping miRNAs. These 11 miRNAs were ranked highest among all of the miRNAs (Table 2). We found that four miRNAs (miR-130a, miR-20a, miR-19a and miR133b) existed in the miR2Disease in the top 10 miRNAs (Table 1). Using PubMed, four miRNAs – miR-520h, miR-133a, miR-34 and miR-103 – were reported to have an intimate relationship with lung cancer.

Figure 2 Micro ribonucleic acid (miRNA)-targeted differentially expressed gene regulation networks. The green nodes are miRNAs and the pink nodes are differentially expressed target genes.
Discussion

In this study, our experimental design primarily found featured miRNAs associated with lung cancer based on bioinformatics. We identified 5572 DEGs between lung cancer and control specimens. After constructing miRNA regulating DEG networks, we obtained 398 miRNA-target interactions, 57 miRNAs, and 321 DEGs. Using the CancerResource and MiR2Disease databases, we finally obtained the top 10 significantly featured miRNAs related to the development of lung cancer; using PubMed, four miRNAs – miR-520h, miR-133a, miR-34 and miR-103 – were reported to have an intimate relationship with lung cancer. As shown in Figure 2, miR-520h shows interaction with SMAD6 and ABCG2. PKM2 is a direct target for miR-133a. VAMP2 and GPD1 are targets for miR-34 and miR-103, respectively.

A recent study reports that miR-520h is a mediator in suppressing the progression of lung cancer. Resveratrol, served as a component in Chinese herbs, can suppress various tumor activities, such as lung cancer. Resveratrol can suppress the migratory ability of tumor cells to lungs by regulating the miRNA-520h-mediated signal cascade. It has been demonstrated that ABCG2 is overexpressed in human cancers and hsa-miR-520h can downregulate ABCG2 in pancreatic cancer to inhibit migration and invasion.

Another recent study indicates that the expression of miR-133a significantly declined in lung squamous cell carcinoma compared with normal tissues. miR-133a, as a tumor suppressor, shows a significant effect in inhibiting tumor cell proliferation. PKM2, as a protein kinase and a transcriptional coactivator, represents an attractive target for cancer therapy. Increased expression of PKM2 can provide advantages for diverse cancer cell growth and survival. Recent studies show that miR-133a is a targeting transcript of PKM2 and the overexpression of PKM2 is associated with the downregulation of miR-133a. We can infer that miR-133a may play an important role in lung cancer by regulating PKM2.

Table 1 The rank of miRNAs related to lung cancer

| miRNA    | avg_Target_rank_sum | Rank |
|----------|---------------------|------|
| miR-130a | 123                 | 1    |
| miR-20a  | 193                 | 2    |
| miR-520h | 475.5               | 3    |
| miR-19a  | 566                 | 4    |
| miR-133a | 606                 | 5    |
| miR-133b | 606                 | 6    |
| miR-103  | 749                 | 7    |
| miR-34   | 878                 | 8    |
| miR-370  | 1217                | 9    |
| miR-148  | 1707                | 10   |
| miR-23a  | 1774                | 11   |
| miR-133  | 1808.5              | 12   |
| miR-199  | 1855                | 13   |
| miR-9    | 1855                | 14   |
| miR-15a  | 1855                | 15   |
| miR-29b-1| 1855                | 16   |
| miR-124a | 1855                | 17   |
| miR-373  | 2019                | 18   |
| miR-24   | 2051                | 19   |
| miR-210  | 2300                | 20   |
| miR-29a  | 2312                | 21   |
| miR-125a | 2350.5              | 22   |
| miR-221  | 2395                | 23   |
| miR-34a  | 2403                | 24   |
| miR-29b  | 2540.5              | 25   |
| miR-140  | 2620                | 26   |
| miR-376a-5p| 2759              | 27   |
| miR-155  | 2766                | 28   |
| miR-124  | 2820                | 29   |
| miR-129  | 2836                | 30   |
| miR-16   | 2868                | 31   |
| let-7b   | 2876                | 32   |
| miR-1b   | 2949                | 33   |
| miR-30   | 2985                | 34   |
| let-7g   | 3072                | 35   |
| miR-98   | 3072                | 36   |
| miR-1    | 3148                | 37   |
| let-7    | 3225                | 38   |
| miR-127  | 3242                | 39   |
| miR-27a  | 3297                | 40   |
| miR-126  | 3332                | 41   |
| LNA_let-7b| 3440               | 42   |
| miR-29c  | 3462                | 43   |
| miR-206  | 3955                | 44   |
| miR-21   | 4144                | 45   |
| miR-222  | 4250                | 46   |
| miR-145  | 4349                | 47   |
| miR-181b | 4510                | 48   |
| miR-376a-5p| 4560              | 49   |
| miR-199a | 4696                | 50   |
| miR-17-5p| 4904                | 51   |
| miR-20   | 4904                | 52   |
| miR-15   | 5006                | 53   |
| miR-15b  | 5006                | 54   |
| miR-10a  | 5082                | 55   |
| miR-27b  | 5381                | 56   |
| miR-199b | 5398                | 57   |

miRNA – micro ribonucleic acid.

Table 2 Known 11 miRNAs related to lung cancer rank

| miRNA    | Rank |
|----------|------|
| miR-130a | 1    |
| miR-20a  | 2    |
| miR-19a  | 4    |
| miR-133b | 6    |
| miR-210  | 20   |
| miR-29a  | 21   |
| miR-125a | 22   |
| let-7g   | 35   |
| miR-1    | 37   |
| miR-126  | 41   |
| miR-21   | 45   |

miRNA – micro ribonucleic acid.
In addition, in mammals, the miR-34 family comprises three processed miRNAs, including miR-34a, which is highly expressed in the brain, and miR-34b/c, which is mainly expressed in the lung.39,40 miRNA-34 has a tumor suppression function in lung cancer.41 Exogenous miRNA-34 can reduce the proliferation and invasion of lung cancer epithelial cells. Moreover, the aberrant expression of miR-103 is found in metastasis-associated gene 1 silencing lung cancer cells.32 The differential expression of miR-103 is closely related with lung cancer progression. VAMP2 is thought to participate in neurotransmitter release. However, little is known about miR-34 regulating VAMP2 in lung cancer.

Four miRNAs (miRNA-130a, miRNA-20a, miRNA-19a and miR-133b) are related with lung cancer based on the miR2Disease database. miRNA-130a has been suggested as a novel prognostic marker for NSCLC patients.33 miRNA-130a is differentially expressed in smoking patients with NSCLC compared with non-smoking ones. A previous study has also shown that miRNA-130a was able to inhibit tumor migration of NSCLC.34 The expression of miRNA-19a was found to be downregulated in lung cancer tissues compared with controls.35 The low expression of miRNA-19a is related to a poor prognosis in patients with lung cancer. Numerous studies have suggested that the expression of miRNA-133b is involved in various cancer progressions.36–38 The expression of miRNA-133b is decreased in lung cancer cells and functions in inducing apoptosis in tumor cells.39 Although evidence of miRNA-20a regulating lung cancer development is insufficient, previous studies have shown that miRNA-20 is differentially expressed in cervical cancer and has been considered to be a prognostic marker for oral squamous tumors.40–42 The relationship between miRNA-20a and lung cancer needs to be further investigated.

Conclusion

Our study more intuitively shows the relationship between miRNA and DEGs in lung cancer than previous reports. We ordered miRNAs based on reasonable indicators and obtained four miRNAs related to lung cancer reported in the literature. The featured miRNAs identified in our paper play key roles in the initiation and progression of lung cancer and may be potential targets for lung cancer treatment. Further research is required to more closely investigate the exact mechanism of lung cancer.

Disclosure

No authors report any conflict of interest.

References

1 Teng XD. [World Health Organization classification of tumours, pathology and genetics of tumours of the lung]. Zhonghua Bing Li Xue Za Zhi 2005; 34: 544–6. (In Chinese.)
2 Cagle PT, Allen TC. Lung cancer genotype-based therapy and predictive biomarkers: present and future. Arch Pathol Lab Med 2012; 136: 1482–91.
3 Lam WK, Watkins DN. Lung cancer: future directions. Respirology 2007; 12: 471–7.
4 Lehto RH, Wyatt G. Perceptions about using mindfulness therapy: a lung cancer focus group study. Cancer Nurs 2013; 36: E51–60.
5 Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Annu Rev Med 2003; 54: 73–87.
6 Yokota J, Kohno T. Molecular footprints of human lung cancer progression. Cancer Sci 2004; 95: 197–204.
7 Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259–69.
8 Esquela-Kerscher A, Trang P, Wiggins JF et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008; 7: 759–64.
9 Fabbri M, Garzon R, Cimmino A et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104: 15805–10.
10 Landi MT, Dracheva T, Rotunno M et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS ONE 2008; 3: e1651.
11 Chen Y, Wu R, Felton J, Rocke DM, Chakicherla A. A method to detect differential gene expression in cross-species hybridization experiments at gene and probe level. Biomed Inform Insights 2010; 2010: 1–10.
12 Ahmed J, Meinel T, Dunkel M et al. CancerResource: a comprehensive database of cancer-relevant proteins and compound interactions supported by experimental knowledge. Nucleic Acids Res 2011; 39: D960–7.
13 Diboun I, Wernisch L, Orenigo CA, Koltzenburg M. Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma. BMC Genomics 2006; 7: 252.
14 Shaffer JP. Controlling the false discovery rate with constraints: the Newman–Keuls test revisited. Biom J Biom Zeitsschrift 2007; 49: 136–43.
15 van der Laan MJ, Dudoit S, Pollard KS. Augmentation procedures for control of the generalized family-wise error rate and tail probabilities for the proportion of false positives. Stat Appl Genet Mol Biol 2004; 3: Article15.
16 Mukherjee S, Chen Z, Gangopadhay A. A privacy-preserving technique for Euclidean distance-based mining algorithms using Fourier-related transforms. Vldb J 2006; 15: 293–315.
17 Chen Z, Liu J, Ng HK et al. Statistical methods on detecting differentially expressed genes for RNA-seq data. BMC Syst Biol 2011; 5 (Suppl 3): S1.
18 Vergoulis T, Vlachos IS, Alexiou P et al. TarBase 6.0: capturing the exponential growth of miRNA targets with experimental support. Nucleic Acids Res 2012; 40: D222–D229.
19 Jiang Q, Wang Y, Hao Y et al. miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res 2009; 37: D98–104.
20 Yu YH, Chen HA, Chen PS et al. MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. Oncogene 2013; 32: 431–43.
21 Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493–506.
22 Dou J, Wen P, Hu W et al. Identifying tumor stem-like cells in mouse melanoma cell lines by analyzing the characteristics of side population cells. Cell Biol Int 2009; 33: 807–15.
23 Wang YH, Li F, Luo B et al. A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. Neoplasma 2009; 56: 371–8.
24 Wang F, Xue X, Wei J et al. hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations. Br J Cancer 2010; 103: 567–74.
25 Moriya Y, Nohata N, Kinoshita T et al. Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J Hum Genet 2012; 57: 38–45.
26 Luo W, Semenza GL. Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol Metab 2012; 23: 560–6.
27 Bluemlein K, Grüning NM, Feichtinger RG, Lehrach H, Kofler B, Raiser M. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2011; 2: 393–400.
28 Wong TS, Liu XB, Chung-Wai Ho A, Po-Wing Yuen A, Wai-Man Ng R, Ignace Wei W. Identification of pyruvate kinase type M2 as potential oncprotein in squamous cell carcinoma of tongue through microRNA profiling. Int J Cancer 2008; 123: 251–7.
29 Lodygin D, Tarasov V, Epanchintsev A et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7: 2591–600.
30 Bommer GT, Gerin J, Feng Y et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17: 1298–307.
31 Kasinski AL, Slack FJ. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 2012; 72: 5576–87.
32 Zhu X, Zhang X, Wang H et al. MTA1 gene silencing inhibits invasion and alters the microRNA expression profile of human lung cancer cells. Oncol Rep 2012; 28: 218–24.
33 Wang XC, Tian LL, Wu HL et al. Expression of miRNA-130a in nonsmall cell lung cancer. Am J Med Sci 2010; 340: 385–8.
34 Acunzo M, Visone R, Romano G et al. miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene 2012; 31: 634–42.
35 Jusufovic E, Keser D, Zukic E, Sejdinovic R, Mrsic D. Downregulated anti-angiogenic miR-19a, miR-126 and let-7b in non-small lung cancer have poor but different prognostic values in squamous and adenocarcinoma subtypes. Eur Respir J 2013; 42 (Suppl. 57): Abstract 3488.
36 Kano M, Seki N, Kikkawa N et al. miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 2010; 127: 2804–14.
37 Bandrés E, Cubedo E, Agirre X et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006; 5: 29.
38 Akcakaya P, Ekelund S, Kolosenko I et al. miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer. Int J Oncol 2011; 39: 311–18.
39 Crawford M, Batte K, Yu L et al. MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun 2009; 388: 483–9.
40 Zhao S, Yao DS, Chen JY, Ding N. Aberrant expression of miR-20a and miR-203 in cervical cancer. Asian Pac J Cancer Prev 2013; 14: 2289–93.
41 Chang CC, Yang YJ, Li YJ et al. MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma. Oral Oncol 2013; 49: 923–31.